To investigate the therapeutic mechanism of the BRD4 inhibitor JQ1
as oral squamous cell carcinoma, renal cell carcinoma, and SACC. [8] [9] [10] Moreover, emerging studies have shown that BRD4 could serve as a therapeutic target for these malignancies. JQ1, a small molecule BRD4 inhibitor, suppresses the progression of a variety of malignancies, including SACC. [11] [12] [13] [14] Recent reports have shown a close association between BRD4 and c-Myc expression in SACC. Located on chromosome 8q24, the protooncogene c-Myc is one of the genes most frequently involved in human carcinogenesis and may be a target of BRD4 inhibition. 15 CMyc controls a variety of cellular functions, including cell cycle progression, growth, survival, and adhesion. 16 It is overexpressed in many malignancies including SACC, and inhibiting its activity and signaling has emerged as a highly attractive therapeutic option for treating SACC. [17] [18] [19] However, it has not to be demonstrated that JQ1 exerts antitumor activity through a c-Myc-dependent pathway in SACC.
The receptor tyrosine kinase epidermal growth factor receptor (EGFR) is a member of the ErbB family of signaling receptors. Aberrant EGFR activation is involved in the development and progression of many cancers. EGFR overexpression has also been found in
SACC. Moreover, inhibitors targeting EGFR and its downstream
pathways have been tested in clinical trials. 20, 21 Our previous study indicated that although JQ1 showed great promise as a cancer therapy, apoptosis rates in JQ1-treated SACC-83 cells suggested these cells are not particularly sensitive to JQ1. Thus, BRD4-targeted single-agent therapies may not provide great therapeutic responses.
Furthermore, emerging studies have shown that some cancer cells can acquire JQ1 resistance by activating a series of kinases including EGFR, which allows tumors to escape therapy. [22] [23] [24] Whether EGFRmediated resistance mechanisms are involved in SACC resistance to JQ1 is largely unknown.
The convergence of the c-Myc and EGFR pathways has contributed to a strong synergic effect in ovarian cancer, endometrial cancer, and T-cell acute lymphoblastic leukemia. [25] [26] [27] To date, there have been no reports regarding such combinatorial treatment in SACC. Thus, a better understanding of the functional and signaling bases of these inhibitors will be crucial for their potential treatment application.
In this study, we aimed to determine the therapeutic mechanism of JQ1 in SACC-83 cells and explore strategies to enhance its therapeutic potential. Our results revealed that the c-Myc pathway was markedly inhibited by JQ1 in SACC-83 cells, which produced certain therapeutic effects. Nevertheless, the EGFR pathway was strongly activated in SACC-83 cells via gene amplification and at the protein level after treatment, which led to JQ1 resistance. 
| Cell viability assay
The effect of JQ1 on cell viability was determined with CCK8 assays (Dojindo, Kumamoto, Japan). SACC-83 cells were seeded into 96-well plates overnight and then treated with JQ1, BKM120, or the combination. Then, 10ul CCK8 was added to each well after 1, 2, 3, and 4 day of exposure. The absorption was acquired at 450 nm using a microplate reader to determine the cell viability. 
| Quantitative RT-PCR (qRT-PCR) assay
Total RNA was extracted using TRIzol reagent (TaKaRa Biotech, Shiga, Japan) after 24 h according to the manufacturer's protocol and reverse transcribed into cDNA using a Reverse Transcriptase kit (TaKaRa Biotech). PCR amplification was performed using the SYBR Green PCR Mastermix Kit (Toyobo). All quantifications were normalized to the level of endogenous control GAPDH. Relative quantity of recommendations. Then, JQ1 was added at a concentration of 0.2, 1, 5 μM after 2 day. Cell proliferation was measured using CCK8 assay, and qRT-PCR and Western blotting were used to measure mRNA and protein levels, respectively.
| Statistical analysis
All data were analyzed and expressed as the mean ± SEM from at least three replicates for each experiment. SPSS 16.0 software (Chicago, IL, USA) was used for data analysis. The significance of differences between the experimental groups and the control group was analyzed using One-way ANOVA. P < 0.05 was considered statistically significant.
| RESULTS

| BRD4 is overexpressed in SACC patients
We first explored BRD4 expression in SACC using immunohisto- Furthermore, qRT-PCR data indicated that the EGFR mRNA was significantly increased after JQ1 treatment ( Figure 3C ). These findings support a role for JQ1-induced EGFR pathway activation underlying the mechanism of JQ1 resistance.
| Combined JQ1 and PI3K inhibition markedly enhanced SACC-83 cells treatment efficacy
To test whether concurrently targeting EGFR-mediated signaling pathways with JQ1 treatment could block JQ1 resistance, we analyzed the proliferation and apoptosis rates of SACC-83 cells treated with JQ1
and the PI3K inhibitor BKM120. These results showed that combined treatment led to a significant decrease in SACC-83 cell viability compared with either inhibitor alone ( Figure 4B,C) . Flow cytometry verified that the combination treatment markedly increased apoptosis rates ( Figure 4E ). Moreover, SACC-83 cells under combined treatment were found to have significantly increased cleaved caspase-3 levels compared with JQ1 or BKM120 used alone ( Figure 4D ). These observations implicated a broad functional collaboration between JQ1 and BKM120 in SACC, particularly regarding cell proliferation and survival.
| The functional cooperation between JQ1 and
BKM120 is due to co-downregulation of the EGFR and c-Myc pathways in SACC-83 cells
Next, SACC-83 cells were treated with JQ1, BKM120, or the combination to understand the mechanism underlying the enhanced 
| EGFR expression modulates the sensitivity of SACC cells to JQ1
To further verify our hypothesis, SACC-83 cells were transfected with EGFR-targeted siRNA (siEGFR) for 2 day, and then treated with qRT-PCR results were consistent with the Western blot data (Figure 6D ). These findings suggested that the sensitivity to JQ1 is associated with EGFR expression in SACC-83 cells.
| DISCUSSION
Despite advances in surgical techniques and postoperative radiotherapy, the overall 10-year survival of SACC patients has not significantly improved. 
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